We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > IBS-D

News List

Microbiome-targeting treatment is set to evolve, address multiple immunological indications: GlobalData expresspharma
July 12, 2021
Microbiome is a space with high potential, a fact underlined by the complete absence of microbiome-targeting treatments on the market.
Final NHS green light for Allergan’s IBS-D drug pharmatimes
September 01, 2017
Allergan’s Truberzi has become the first treatment for irritable bowel syndrome with diarrhoea (IBS-D) to be reviewed and recommended by the National Institute for Health and Care Excellence for use on the NHS in England and Wales.
NICE nod for Allergan’s Truberzi for IBS-D pharmatimes
July 31, 2017
Cost regulators for NHS treatments in England and Wales are backing use of Allergan’s Truberzi to treat irritable bowel syndrome with diarrhoea (IBS-D) in patients who have not responded to or cannot take other treatments.-D
New data reinforce the effectiveness of Viberzi to treat the symptoms associated with IBS-D cphi-online
July 13, 2017
Viberzi proven safe and effective in patients who reported inadequate response to prior loperamide use.